Lung Cancer Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)), By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments), By Region
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationLung Cancer Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)), By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments), By Region
The global lung cancer therapeutics market is projected to witness impressive growth during the forecast period. The factors contributing to the growth of the market are the increasing incidence of lung cancer and sophisticated treatments associated with lung cancer.
Lung cancer therapeutics is a branch of medicine concerned with the treatment of lung cancer which includes radiation therapy, chemotherapy, targeted therapy, immunotherapy, and others. The treatment also includes the adoption of personalized medicines to increase the rate of survival in terms of high proliferation of cancer cells in the lungs.
The introduction of nanomedicines to treat lung cancer and regulatory approvals of medicines are expected to drive the growth of the market during the forecast period. Further, a surge in lung cancer prevalence and the dominance of chemotherapy are driving the growth of the market during the forecast period.
Increasing Prevalence of Lung Cancer
(68,820 men and 61,360 women) people died due to lung cancer.
The rise in demand for Immunotherapy
For instance, in 2022, to create innovative immunotherapy medicines for cancer, the Parker Institute for Cancer Immunotherapy collaborated with scientists and business pioneers.
Side Effects of cancer treatment
Lung cancer is a chronic disease with lengthy treatments. These treatments affect the human body due to high and long exposure to drugs. Some of the common side effects related cancer curing drugs include breathing problems, fatigue, infection, bleeding, anemia, Stomach problems (nausea, vomiting, diarrhea, or constipation), changes in appearance, hair fall, and others. For instance, Chemotherapy attacks cancer cells, but it also impacts some healthy cells in the hair follicles, blood, mouth, and digestive system. Moreover, side effects vary from person to person and the dose used to treat cancer. Hence, the side effects of cancer treatment are projected to hamper the growth of the market.
Download Free Sample Report
Market Segmentation
The global lung cancer therapeutics market is segmented based on
Recent Developments
- InMarch 2019, AdoRx Treatments Limited announced a strategic alliance withJohnson & Johnson Innovation LLC and the Lung Cancer Initiative at Johnson& Johnson (LCI) for the creation of brand-new, innovative lung cancertherapeutics.
Market players
AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Merck & Co, Pfizer Inc., Allergan Inc., Teva Pharmaceutical Industries Ltd., Abbvie, Inc., Johnson & Johnson, Amgen Inc., Novartis AG among others are the major players in the Global Lung Cancer Therapeutics Market.
| Attribute | Details |
| Base Year | 2022 |
| Historic Data | 2018 – 2021 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028 |
| Report coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments covered | Cancer Cell Type Treatment |
| Regional scope | North America; Asia Pacific; Europe; South America; Middle East & Africa |
| Country scope | United States; Canada; Mexico; China; India; Japan; Australia; South Korea; Germany; France; United Kingdom; Spain; Italy; Brazil; Argentina; Colombia; South Africa; UAE, Saudi Arabia; Turkey; Egypt. |
| Key companies profiled | AstraZeneca, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, Hoffmann-La Roche, Merck & Co, Pfizer Inc., Allergan Inc., Teva Pharmaceutical Industries Ltd., Abbvie, Inc., Johnson & Johnson, Amgen Inc., Novartis AG among others. |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy